A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 16 Apr 2018 This trial has been completed in Germany, according to European Clinical Trials Database
- 11 Jan 2018 Planned end date changed from 19 Apr 2018 to 26 Apr 2018.
- 11 Jan 2018 Planned primary completion date changed from 19 Apr 2018 to 26 Apr 2018.